Analysts expect that Synlogic Inc (NASDAQ:SYBX) will announce $420,000.00 in sales for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Synlogic’s earnings. The highest sales estimate is $630,000.00 and the lowest is $250,000.00. Synlogic reported sales of $350,000.00 in the same quarter last year, which indicates a positive year-over-year growth rate of 20%. The firm is scheduled to announce its next earnings results on Tuesday, May 21st.

On average, analysts expect that Synlogic will report full year sales of $1.92 million for the current financial year, with estimates ranging from $1.30 million to $2.50 million. For the next fiscal year, analysts forecast that the company will report sales of $1.65 million, with estimates ranging from $1.25 million to $2.40 million. Zacks’ sales calculations are an average based on a survey of analysts that follow Synlogic.

Synlogic (NASDAQ:SYBX) last announced its earnings results on Tuesday, March 12th. The biotechnology company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.09. Synlogic had a negative net margin of 1,922.02% and a negative return on equity of 36.38%. The company had revenue of $0.11 million during the quarter, compared to analysts’ expectations of $0.24 million.

Several analysts recently commented on the stock. BTIG Research began coverage on shares of Synlogic in a report on Tuesday, February 12th. They set a “buy” rating and a $22.00 price target for the company. Zacks Investment Research downgraded shares of Synlogic from a “buy” rating to a “hold” rating in a research report on Saturday, January 5th. Chardan Capital reissued a “buy” rating and set a $20.00 target price on shares of Synlogic in a research note on Tuesday, March 12th. HC Wainwright set a $20.00 target price on shares of Synlogic and gave the stock a “buy” rating in a research report on Monday, December 10th. Finally, ValuEngine lowered Synlogic from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Synlogic currently has an average rating of “Buy” and an average target price of $18.47.

Shares of SYBX traded up $0.03 during mid-day trading on Tuesday, reaching $8.48. The company’s stock had a trading volume of 79,129 shares, compared to its average volume of 70,431. The firm has a market capitalization of $216.92 million, a P/E ratio of -4.18 and a beta of 2.36. Synlogic has a 1 year low of $5.75 and a 1 year high of $14.59.

In other news, insider Paul Francis Miller sold 9,000 shares of the business’s stock in a transaction on Wednesday, February 13th. The shares were sold at an average price of $9.75, for a total value of $87,750.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 23.30% of the company’s stock.

A number of institutional investors have recently modified their holdings of the stock. Legal & General Group Plc acquired a new stake in shares of Synlogic during the third quarter worth about $33,000. American International Group Inc. bought a new stake in shares of Synlogic in the third quarter valued at about $145,000. Rhumbline Advisers grew its holdings in shares of Synlogic by 45.7% during the fourth quarter. Rhumbline Advisers now owns 21,753 shares of the biotechnology company’s stock worth $152,000 after buying an additional 6,820 shares in the last quarter. TIAA CREF Investment Management LLC bought a new position in shares of Synlogic during the third quarter worth about $251,000. Finally, Fosun International Ltd acquired a new position in shares of Synlogic during the 4th quarter worth about $286,000. 81.05% of the stock is currently owned by institutional investors and hedge funds.

About Synlogic

Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy, which is in Phase I clinical trial for the treatment of patients with liver disease and hepatic encephalopathy, and urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.

Further Reading: What are municipal bonds?

Get a free copy of the Zacks research report on Synlogic (SYBX)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Synlogic (NASDAQ:SYBX)

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with's FREE daily email newsletter.